1	Genetic Associations of Lipid-Lowering Drugs and Parkinson's Disease: A Mendelian
2	Randomization Study
3 4 5 6	Lin Shen MSc <sup>*1</sup> , Yifan Yang MSc <sup>*2</sup> , Yi Li PhD <sup>1</sup> , Hok Leong Chin <sup>3</sup> , Helen Huang <sup>4</sup> , Bernard Man Yung Cheung MB BChir PhD FRCP <sup>5</sup> , Gary Tse MD PhD FRCP FRCPath <sup>6,7</sup> , Oscar Hou In Chou MSc <sup>3</sup> <i>#</i> , Jiandong Zhou PhD <sup>8,9</sup> <i>#</i>
7	
8	<sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,
9	Shaanxi Province, China
10	<sup>2</sup> School of Management, Xi'an Jiaotong University, Xi'an, China
11	<sup>3</sup> Division of Neurology, Department of Pediatrics, University of Chicago, Chicago, IL, USA
12	<sup>3</sup> Division of Clinical Pharmacology and Therapeutics, Department of Medicine, University of Hong
13	Kong, Hong Kong, China
14 15	<sup>4</sup> Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China
16	<sup>5</sup> School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,
17	China
18	<sup>6</sup> Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of
19	Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin
20	300211, China
21	<sup>7</sup> Kent and Medway Medical School, Canterbury, United Kingdom
22	<sup>8</sup> Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University
23	of Hong Kong, Hong Kong, China
24	<sup>9</sup> Division of Health Science, Warwick Medical School, University of Warwick, United Kingdom
25	
26	* Co-first authors
27	# Correspondence to:
28	Oscar Hou In Chou, MSc,
29	Division of Clinical Pharmacology and Therapeutics, Department of Medicine, School of Clinical
30	Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
31	Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong,
32	China
33	Email: gary.tse@kmms.ac.uk
34	
35	Jiandong Zhou, Ph.D.
36	Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of
37	Hong Kong, Hong Kong, China
38	Division of Health Science, Warwick Medical School, University of Warwick, United Kingdom
39	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 40 Abstract

Background: There is a need to establish the role of lipid-lowering agents as a therapeutic option for
Parkinson's Disease (PD), but its associations remain elusive. This study investigated genetic variants
proxying lipid-lowering agents through HMGCR, NPC1L1, and PCSK9 inhibitors to determine casual
associations with PD risk.

**Methods:** We utilized a two-sample Mendelian randomization (MR) framework, where low-density 45 lipoprotein (LDL) was the outcome of interest. Genetic associations with LDL were extracted from the 46 Global Lipids Genetics Consortium. Summary statistics for PD were extracted from two GWAS 47 datasets, consistent of 1,843 PD cases and 216,630 control in the first dataset and 1,570 PD cases and 48 1,259 controls in the second dataset. Instrumental variables (IV) were optimized with positive control 49 analyses on cardiovascular and metabolic outcomes. IV-exposure associations from LDL GWAS data 50 51 were integrated with IV-outcome associations from the PD GWAS data. The inverse variance weighted method was applied. Bayesian colocalization analysis identified target gene regions for LDL and PD. 52 **Results:** Genetic variations in *HMGCR* were significantly associated with a reduced risk of PD (odds 53 54 ratio [OR] = 0.54, 95% CI 0.34-0.86). However, variation in HMGCR was associated with an increased risk of the tremor-dominant (TD) subtype compared to the postural instability/gait difficulty (PIGD) 55 subtype (OR = 8.43, 95% CI 2.12-33.52). There were trends with increased risk for the TD subtype in 56 57 NPC1L1 and a decreased risk in PCSK9 but these findings did not meet the Bonferroni threshold. We identified two single nucleotide polymorphisms (SNPs) in HMGCR within the same genomic region of 58 close proximity, with rs12916 as the leading SNP associated with LDL and rs10942735 as the leading 59 SNP associated with PD. 60

61 Conclusion: A casual association between HMGCR inhibition and reduced overall PD risk was

62 identified, but there were increased the risks of tremor-dominant subtypes.

63

- 64 Keywords: Low-density lipoprotein, Parkinson's disease, lipid-lowering drug, mendelian
- 65 randomization, single nucleotide polymorphisms

#### 66 Introduction

67 Parkinson disease (PD) is the second most common neurodegenerative disease with progressive nature<sup>1</sup>. In 2017, there were 1.02 million incident cases of PD as reported by the Global Burden of 68 Disease<sup>2</sup>. The determinants of PD are multifactorial, with age-related susceptibilities being the biggest 69 risk factor for PD with a median onset of 60 years of age<sup>3</sup>. Various studies have identified that genetic 70 susceptibility could modify the effects of environmental stressors. In a recent meta-analysis of 71 genome-wide association studies, 70 variants involved with the folding of alpha-synuclein may 72 contribute to PD risk suggesting a genetic etiology<sup>4-6</sup>. Unfortunately, there are a lack of therapies that 73 could delay the progression of disease. 74

With recent advancements in surrounding lipid-lowering therapies, targets of cholesterol metabolism 75 76 may be of interest in PD. Lipids are becoming increasingly recognized to play a significant role in PD. Alpha synuclein is highly expressed in the brain, the second most lipid-rich organ, and exhibits binding 77 properties with lipid membranes, thereby altering their structure and resulting in the formation of 78 79 toxic alpha-synuclein oligomers<sup>7,8</sup>. There is much interest on how lipid aberrations could contribute to PD, as several risk genes exert known lipid-related functions<sup>9</sup>. An increase in serum lipids such as 80 low-density lipoprotein (LDL) and its metabolites are correlated with oxidative stress in the brain 81 through the generation of Lewy bodies, though there are conflicting studies suggesting that 82 83 cholesterol and triglyceride levels are neuroprotective<sup>10-13</sup>. The role of lipid-lowering agents, such as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors, Niemann-Pick C1-like 1 (NPC1L1) 84 inhibitor, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may be of therapeutic 85 interest to ameliorate PD risk by targeting brain cholesterol metabolism and associated pathways but 86

<sup>87</sup> further studies are required to clarify these outcomes due to the bidirectional effect of lipids in PD<sup>14</sup>.

In this study, we leveraged genetic variants proxying LDL lowering agents through HMGCR, NPC1L1, 88 89 and PCSK9 inhibitors to determine its association with PD. Genetic proxies have been successfully used to study the effect of lipid-lowering drugs which target alleles encoding various molecular stages 90 in VLDL trafficking and cholesterol metabolism<sup>15</sup>. To establish casual associations of modifiable 91 exposures such as genetic proxies for lipid-lowering therapies in PD, we utilized a two-sample 92 Mendelian randomization (MR) framework to reduce reverse causation biases and less likely to be 93 influenced by confounding factors<sup>15</sup>. This study aimed to investigate the relationship between lipid-94 lowering medication and PD. 95

96

#### 97 Methods

#### 98 Study Design

MR is a statistical technique that utilizes genetic variants as instrumental variables (IVs) to establish causal inferences between exposures and outcomes. This study employed the two sample MR framework to investigate the effects of genetic variation in lipid-lowering drug targets on the risk of Parkinson's disease (PD)<sup>16</sup>. Exposure and outcome data were extracted from public genome wide association study (GWAS) summary datasets conducted on two independent, non-overlapping populations. risk of Parkinson's disease. The details of the framework are presented in **eFigure 1**.

#### 105 LDL GWAS Data

Due to the unavailability of GWAS data on the exposure (protein targets of lipid-lowering drugs) and considering reducing LDL levels is a confirmed physiological response to lipid-lowering drug treatment, our study opts to use the available LDL as a biomarker of interest. This choice enables us to infer the effects of genetic variations in lipid-lowering drugs on the. Genetic associations with LDL were extracted from the largest GWAS dataset conducted by the Global Lipids Genetics Consortium, involving 1.3 million individuals of European ancestry. The details of primary study is provided in reference<sup>17</sup>.

#### 113 Parkinson's Disease GWAS Data

The summary statistics for PD were extracted from the two GWAS datasets, which were published by the International Parkinson's Disease Genomics Consortium. The first GWAS dataset consisted of 1,843 cases and 216,630 controls<sup>6</sup>. The other GWAS dataset focused on the motor subtype of PD consisted of 1,570 cases and 1,259 controls, where the tremor-dominant (TD) was defined as 1 and considered the case group, and the postural instability/gait difficulty (PIGD) was defined as 0 and served as the control group<sup>18</sup>. Both GWAS dataset were conducted on individuals of European ancestry to minimize potential bias from population stratification.

#### 121 Instrument Selection

The IVs in this study were screened for the genes that encode lipid-lowering drug target proteins. Variations within and around these genes were used to assess the effect of drug use on exposure factors and outcomes. Three major classes of lipid-lowering drugs were identified, including 3hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors, Niemann-Pick C1-like 1 (NPC1L1)

- 126 inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Detailed information
- about the protein targets and encoding genes for these drugs is provided in **Table 1**.

The single-nucleotide variations (SNVs) were designated within each encoding gene (within ±100kb base pairs of the gene location). Following this, variants with p-values greater than 5\*10-8 and a minor allele frequency (MAF) below 0.01 werwe excluded in the GWAS data for LDL. The remained variants for each lipid-lowing drug target were selected as IVs and clumped with an R<sup>2</sup> of 0.1, a window size of 10000 kb, and the reference population set to EUR. The detailed screening process of IVs for lipid-lowering drug is shown in **Figure 1**.

#### 134 **Positive Control Analyses**

In order to substantiate IVs selection, positive control analyses were performed using hyperlipidemia
 and coronary artery disease (CAD) as outcomes. Furthermore, three obesity-related traits were used
 as additional outcomes for validation, including body mass index (BMI), waist circumference (WC),
 and hip circumference (HC).

#### 139 Statistical Analysis

The present investigation integrated the IV-exposure association derived from the LDL GWAS data with the IV-outcome association obtained from the Parkinson's disease GWAS data to create harmonized data for the MR study. To safeguard the validity of the IV, it is crucial to adhere to three fundamental assumptions. The initial assumption, known as relevance, necessitates that the genetic variants are significantly associated with the exposure. Evaluation of the strength of the IV was conducted through the computation of F statistics, derived as the square of the beta divided by the

square of the standard error, with F statistics exceeding 10 indicatives of robust IV strength. The 146 second assumption, independence, posits that the genetic variants remain unaffected by potential 147 confounding factors, a condition typically fulfilled owing to the random assortment of genetic variants 148 149 during conception. The third assumption, exclusion restriction, asserts that the variants exclusively influence the outcome through the designated exposure, thereby precluding horizontal pleiotropy. 150 Evaluation of horizontal pleiotropy was conducted utilizing the MR Egger method, and non-significant 151 152 results suggest the absence of horizontal pleiotropy. In instances where all three assumptions are met, the Inverse Variance Weighted (IVW) method is applied to yield unbiased causal estimates pertaining 153 154 to the associations between exposures and outcomes.

The F-statistic was calculated by dividing the square of beta by the square of the standard error, where an F-statistic value greater than 10 indicating sufficient instrument strength. The Cochran Q test was employed to assess heterogeneity within IVs, and non-significant results signify the absence of heterogeneity. To mimic the LDL-lowering effects of lipid-lowering drugs, the MR estimates were standardized to a 1 mmol/L decrease in LDL. Following Bonferroni corrected principle, the significance level of multiple testing for 3 drugs classes was set as *p* value < 0.017 (0.05/3).

For the lipid-lowering drugs identified to be associated with Parkinson's disease, Bayesian colocalization analysis was conducted specifically within the target gene region for LDL and Parkinson's disease. Another sensitivity analysis was the leave-one-out method, which entails systematically excluding each variant within the drug's target gene region and subsequently calculating the meta-effects of the remaining variants. The absence of statistically significant changes in MR estimates following the removal of each variant implies the robustness of the obtained results.

All analyses were performed in R (version = 4.3.1), mainly utilizing the TwoSampleMR (version = 0.5.7) and coloc (version = 5.2.3) packages. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) MR guidelines.

#### 170 Data Availability

All GWAS data analyzed in this study are publicly available. The LDL GWAS data is downloaded from 171 the website of the Global Lipids Genetics Consortium (https://csg.sph.umich.edu/willer/public/glgc-172 lipids2021). The PD GWAS data is released in the resources page of International Parkinson's Disease 173 174 Genomics Consortium (https://www.pdgenetics.org/resources). The GWAS data for positive control analyses are available through the IEU Open-GWAS Project database (https://gwas.mrcieu.ac.uk/). 175 The corresponding GWAS-ids are ebi-a-GCST90104006 for hyperlipidemia; ebi-a-GCST003116 for 176 177 coronary artery disease; ieu-b-40 for BMI; ukb-b-9405 for WC and ukb-b-15590 for HC. All code for MR analyses is available in a GitHub repository. 178

179

#### 180 Results

#### 181 Instrument Selection

For the primary analysis, 22 variants were selected to proxy LDL lowering through inhibition of HMGCR (mean F-statistic of 194), 12 for NPC1L1 (mean F-statistic of 109), and 37 for PCSK9 (mean Fstatistic of 286). Detailed data of the IVs to proxy lipid-lowering drugs are shown in **eTable 1**.

185 **Positive Control Analyses** 

As shown in **Figure 2**, genetic variations in *HMGCR*, *NPC1L1*, and *PCSK9* were significantly associated with a reduced risk of hyperlipidemia and CAD (**Figure 2**, **panels A and B**). For obesity-related traits (**Figure 2**, **panels C-E**), genetic variation in *HMGCR* was significantly correlated with increased BMI, WC, and HC. However, genetic variations in *NPC1L1* and *PCSK9* demonstrated no apparent correlation with BMI, WC, and HC. Positive control analysis data for each lipid-lowering drug class are available in **eTable 2-6**.

#### 192 Effects of Genetic Variation in lipid-lowering drug Targets on PD risk

We conducted MR analysis using two PD GWAS datasets, and the results are illustrated in **Figure 3**. For the unstratified PD dataset, the MR analysis results revealed a significant association between genetic variation in *HMGCR* and a reduced risk of PD at the Bonferroni-corrected threshold (odds ratio [OR] = 0.54, 95% CI 0.34-0.86, p = 0.009, **Figure 3A**). However, there was no apparent correlation between genetic variations in *NPC1L1* and *PCSK9* and the risk of PD.

Interestingly, further MR analysis on the PD dataset stratified by motor function showed that, 198 compared to the PIGD subtype, genetic variation in HMGCR was significantly associated with an 199 increased risk of the TD subtype at the Bonferroni-corrected threshold (OR = 8.43, 95% CI 2.12-33.52, 200 201 p = 0.0025, Figure 3B). Additionally, genetic variation in NPC1L1 showed a trend toward increased risk 202 for the TD subtype (OR = 13.09, 95% CI 1.03-166.64, p = 0.0475), while genetic variation in PCSK9 203 exhibited a trend toward decreased risk for the TD subtype (OR = 0.28, 95% Cl 0.08-0.94, p = 0.0398). Unfortunately, the *p*-values for MR analysis of these two gene variations exceeded the Bonferroni-204 205 corrected threshold (p < 0.017).

As evidence suggested that cognitive function declines more rapidly, and prognosis is worse in PIGD patients compared to TD patients. Our analysis suggests that the use of HMGCR and NPC1L1 inhibitors may contribute to the transition of PD patients from PIGD subtype to TD subtype, while the use of PCSK9 inhibitors may pose a risk of worsening PD. No heterogeneity or pleiotropy was detected within the IVs in both PD GWAS datasets (**Figure 3**, *p*-values for heterogeneity > 0.05, *p*-values for pleiotropy > 0.05). Detailed MR analysis data are presented in **eTable 7-9**.

#### 212 Sensitivity Analysis

213 Colocalization analysis was conducted for LDL and PD within *HMGCR* (**eTable 10**), as well as co-214 localization analysis for LDL and PD motor subtype within both *HMGCR* and *PCSK9* (**eTable 11**). The 215 results of the colocalization analysis indicated a low probability of shared random variation between 216 LDL and PD within *HMGCR* (0.87%), and similarly low probabilities within both *HMGCR* and *PCSK9* for 217 the motor subtype of PD (5.31% and 8.22%, respectively).

The findings suggest that there is no high probability of shared causal variants for LDL and PD (including the PD motor subtype) within the coding regions of *HMGCR* and *PCSK9*. However, in the regional plot illustrating the associations of LDL and PD within ±100kb of *HMGCR*, rs12916 emerged as the leading SNP associated with LDL, while rs10942735 was identified as the leading SNP associated with PD within the same genomic region. Notably, these two leading SNPs were in close proximity, that revealed a trend of colocalization between LDL and PD (**eFigure 2**).

Additionally, in the PD GWAS datasets, leave-one-out sensitivity analyses were conducted for the genetic variations in *HMGCR* and *PCSK9*. The analyses demonstrated the robustness of the results,

indicating that after excluding each SNP, the overall error lines show minimal changes (all error lines
are either to the right or left of 0), as shown in eFigure 5-7.

228

#### 229 Discussion

This study investigated the effects of genetic variations in lipid-lowering drugs on the PD risk using a combination of LDL genetic dataset in ~1,300,000 participants and two PD genetic datasets, consistent of 1,843 PD cases and 216,630 control in the first dataset and 1,570 PD cases and 1,259 controls in the second dataset. To the best of our knowledge, this is one of the largest studies with strong validation suggesting a causal association between HMGCR inhibition and a reduced risk of PD. Besides, this study was the first MR to investigate the association between genetic variation in lipidlowering drug and the subtypes of PD.

A handful of literature has explored the association between lipid-lowering drugs or serum lipid levels 237 238 and PD, yet the results have been inconsistent <sup>19-26</sup>. In a MR study using a Danish dataset, no association was detected between LDL and the risk of PD, whereas a separate MR study conducted 239 by a Swedish team suggested a causal inverse association of LDL with PD risk<sup>19,27</sup>. Another recent MR 240 study did not project an elevated risk of PD with statin exposure<sup>20</sup>. However, the results lacked 241 242 sufficient precision to conclusively support preventive benefits. Nevertheless, this does not negate the potential advantages of on-target effects associated with statin use for PD prevention through 243 alternative mechanisms<sup>20</sup>. However, all of these MR studies have their own statistical limitations. 244 Other non-MR studies have also reported varied conclusions<sup>21-25</sup>. Interpreting the above studies 245

alongside our study results, which showed that only HMGCR inhibition, not NPC1L inhibition and 246 PCSK9 inhibition, was correlated with a reduced risk of PD. The result provided evidence that HMGCR 247 inhibitors may modify the pathogenesis of PD through a mechanism different from lowering LDL. 248 Indeed, multiple studies have proposed the protective effects of HMGCR inhibitors on  $\alpha$ -synuclein 249 aggregation through mechanisms such as antioxidation and promotion of neural repair<sup>28-30</sup>. Other 250 suggested mechanisms involve HMGCR inhibitors preventing neuronal injury by mitigating microglia 251 and autophagy activation<sup>31-33</sup>. As HMGCR inhibitors can cause a dose-dependent reduction in 252 coenzyme Q10, the protective effects of HMGCR inhibitors may be compromised by mitochondrial 253 254 dysfunction if the dose surpasses a specific threshold<sup>34</sup>. Nonetheless, this potential explanation for 255 the inconsistency in previous studies warrants further investigation.

256 Another discovery from this study implied that incorporating HMGCR inhibitors may facilitate the shift of PD patients from the less favorable PIGD subtype to the more favorable TD subtype. The 257 258 mechanisms behind the observations in the current study were not fully understood and necessitate additional research. However, previous studies have pointed to the involvement of various neural 259 pathways in contributing to the PIGD phenotype of Parkinson's disease<sup>35-37</sup>. For example, some 260 literature hinted at a connection between the severity of PIGD and amyloid  $\beta$  pathology<sup>35,38</sup>. The 261 262 neuroprotective impact of HMGCR inhibitors on amyloid  $\beta$ -induced neurotoxicity may offer a partial explanation for the effect observed on the PIGD subtype<sup>39</sup>. Other studies suggested that elevated 263 GABA levels or reduced acetylcholine may play a role in the development of the PIGD phenotype in 264 Parkinson's disease, and HMGCR inhibitors might be involved in modifying the pathogenesis<sup>40,41</sup>. 265 266 Given functional network alterations within cerebro-cerebellar motor pathways were identified among PD motor subtypes, we contemplate whether HMGCR inhibitors contribute to the alterations, 267

268 warranting further exploration in future studies<sup>37</sup>.

269 This study possesses several strengths. First, it involves large sample sizes from public GWAS datasets 270 for analysis. The inclusion of such substantial and robust data enables study replication and diminishes random errors. In addition, all the GWAS datasets used were conducted on individuals of 271 272 European ancestry, thereby minimizing potential biases arising from population stratification. Secondly, the two-sample MR study design may overcome the challenges of confounding between 273 the exposure and outcome when estimating the causal exposure-outcome association. It also offers 274 an opportunity to enhance statistical power and avoid reverse causality. Third, by performing a series 275 of positive control analyses and sensitivity analyses that considered different patterns of pleiotropy, 276 this study enhanced the robustness of the results, thereby reinforcing the evidence supporting our 277 278 findings.

The study has several limitations. First, MR study needed to fulfill the instrumental variable 279 assumptions which cannot be empirically verified. Even though rigorous statistical methods were 280 281 employed, it is important to note that the complete exclusion of pleiotropy and bias effects cannot be guaranteed. Second, the lipid-lowering drug effect predicted by MR cannot be directly juxtaposed 282 with the pharmacological effect observed in real life practice. The exposure instrumented by genetic 283 284 variants persists throughout lifetime, whereas pharmacological intervention influences only a specific period of life. Consequently, the results of this study should be interpreted as evaluating the long-285 term modulation effects of drug target proteins. Third, lipid-lowering drugs may modify PD through 286 287 interactions with other protein targets not captured in this MR study or via different mechanisms. Fourthly, the dataset utilized in this study only comprised individuals of European ancestry, limiting 288

- the generalizability of the results to other ethnic groups. However causal effects are expected to be
- 290 consistent across settings unless the mediating mechanisms differ, although the extent of response
- 291 may vary.
- 292
- 293 Conclusion
- 294 The two way Mendelian Randomization result identified the casual association between genetic
- variations in *HMGCR* and PD, which suggested that lipid-lowering drugs may play a role in lowering
- risks of PD. However, the risk of TD subtypes are higher compared to PIGD subtypes, suggesting the
- 297 bidirectional effects of the lipid-lowering drugs.

#### 298 Ethical approval statement

- 299 None.
- 300 Availability of data and materials
- 301 Data are publicly available and can be accessed with the GWASID.
- 302 Conflicts of Interest
- 303 None
- 304 Acknowledgements
- 305 None

#### 306 Funding

- 307 This research received no specific grant from any funding agency in the public, commercial, or not-
- 308 for-profit sectors.
- 309 Guarantor Statement
- 310 All authors approved the final version of the manuscript.

### 311 Author contributions

- 312 L S, YF, JD Z: conception of study, preparation of figures, study design, data contribution, statistical
- analysis, data interpretation, manuscript drafting, and critical revision of the manuscript.

- 314 Y L, HL C, H H: literature search, data interpretation, literature search, data collection, manuscript
- 315 drafting.
- 316 BMY C, G T: critical revision of the manuscript.
- 317 OHI C, JD Z: conception of study and literature search, study design, data collection, and critical
- 318 revision of manuscript, study supervision.

#### 319 References

- Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson's Disease: A Review from Pathophysiology
   to Treatment. *Mini Rev Med Chem* 2020; 20(9): 754-67.
- 322 2. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and
- 323 years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017:
- a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1789858.
- 326 **3.** Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest
- 327 risk factor? *Ageing Res Rev* 2014; **14**(100): 19-30.
- Marras C, Lang A. Parkinson's disease subtypes: lost in translation? *J Neurol Neurosurg Psychiatry* 2013; 84(4): 409-15.
- 5. Kara E, Kiely AP, Proukakis C, et al. A 6.4 Mb duplication of the alpha-synuclein locus causing
- 331 frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. *JAMA Neurol* 2014;
- 332 **71(9)**: **1162-71**.
- 333 6. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and
- heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*
- 335 *Neurol* **2019**; **18**(12): **1091-102**.
- 7. Fanning S, Selkoe D, Dettmer U. Parkinson's disease: proteinopathy or lipidopathy? *NPJ Parkinsons Dis* 2020; 6: 3.
- Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of alpha-Synuclein Neurotoxicity
   Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. *Mol Cell* 2019; **73**(5): 1001-14
   e8.

- 341 9. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of
- 342 Parkinson disease. *Neurology* 2008; **70**(21): 1972-9.
- 10. Xicoy H, Klemann CJ, De Witte W, Martens MB, Martens GJ, Poelmans G. Shared genetic etiology
- between Parkinson's disease and blood levels of specific lipids. *NPJ Parkinsons Dis* 2021; **7**(1): 23.
- 11. Jin U, Park SJ, Park SM. Cholesterol Metabolism in the Brain and Its Association with Parkinson's
- 346 Disease. Exp Neurobiol 2019; 28(5): 554-67.
- 12. Galper J, Dean NJ, Pickford R, et al. Lipid pathway dysfunction is prevalent in patients with
- 348 Parkinson's disease. Brain 2022; **145**(10): 3472-87.
- 13. Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson's disease
- 350 risk: A statin-free cohort study. *Mov Disord* 2018; **33**(8): 1298-305.
- 351 14. Williams DM, Bandres-Ciga S, Heilbron K, et al. Evaluating Lipid-Lowering Drug Targets for
- 352 Parkinson's Disease Prevention with Mendelian Randomization. Ann Neurol 2020; 88(5): 1043-7.
- 353 15. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nat Rev Methods* 354 *Primers* 2022; 2.
- 355 16. Schmidt AF, Finan C, Gordillo-Maranon M, et al. Genetic drug target validation using Mendelian
   356 randomisation. *Nat Commun* 2020; **11**(1): 3255.
- **17.** Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association
- 358 studies of lipids. *Nature* 2021; **600**(7890): 675-9.
- 359 18. Alfradique-Dunham I, Al-Ouran R, von Coelln R, et al. Genome-Wide Association Study Meta-
- 360 Analysis for Parkinson Disease Motor Subtypes. *Neurol Genet* 2021; **7**(2): e557.
- 19. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen AJb. Low LDL cholesterol, PCSK9
- 362 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian

- 363 randomisation study. 2017; **357**.
- 364 20. Williams DM, Bandres-Ciga S, Heilbron K, et al. Evaluating lipid-lowering drug targets for
- Parkinson's disease prevention with mendelian randomization. 2020; **88**(5): 1043-7.
- 21. Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson's disease
- 367 risk: a statin-free cohort study. 2018; **33**(8): 1298-305.
- 22. Lee HJ, Han K, Kim YW, Yang SN, Yoon SYJP, Disorders R. Association between lipid levels and the
- 369 risk of Parkinson's disease in individuals with diabetes mellitus: A nationwide population-based
- 370 cohort study. 2023; 117: 105881.
- 23. Nguyen TTH, Fournier A, Courtois É, et al. Statin Use and Incidence of Parkinson's Disease in
- Women from the French E3N Cohort Study. 2023.
- 24. Yan J, Qiao L, Tian J, et al. Effect of statins on Parkinson's disease: A systematic review and metaanalysis. 2019; 98(12).
- 25. Jeong SH, Lee HS, Chung SJ, et al. Effects of statins on dopamine loss and prognosis in Parkinson's
- 376 disease. 2021; **144**(10): 3191-200.
- 26. Zhao Y, Gagliano Taliun SAJFiN. Lipid-lowering drug targets and Parkinson's disease: A sex-specific
- 378 Mendelian randomization study. 2022; **13**: 940118.
- 27. Fang F, Zhan Y, Hammar N, et al. Lipids, Apolipoproteins, and the risk of Parkinson disease: a
- prospective cohort study and a Mendelian randomization analysis. 2019; 125(6): 643-52.
- 381 28. Eriksson I, Nath S, Bornefall P, Giraldo AMV, Öllinger KJEjocb. Impact of high cholesterol in a
- 382 Parkinson's disease model: Prevention of lysosomal leakage versus stimulation of  $\alpha$ -synuclein
- 383 aggregation. 2017; **96**(2): 99-109.
- 384 29. Yan J, Sun J, Huang L, Fu Q, Du GJJonr. Simvastatin prevents neuroinflammation by inhibiting N-

methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. 2014; **92**(5): 634-40.

386 **30**. Tan W, Xue-bin C, Tian Z, et al. Effects of simvastatin on the expression of inducible nitric oxide

387 synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of

388 Parkinson disease. 2016; **126**(3): 278-86.

389 31. Lu D, Shen L, Mai H, et al. HMG-CoA reductase inhibitors attenuate neuronal damage by
 390 suppressing oxygen glucose deprivation-induced activated microglial cells. 2019; 2019.

391 32. Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar AJB. The effects of

392 statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. 2020;

**46(3): 309-25**.

394 33. Kang SY, Lee S-B, Kim HJ, Kim H-T, Yang HO, Jang WJNL. Autophagic modulation by rosuvastatin

395 prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease. 2017; 642: 20-6.

396 34. Apostolopoulou M, Corsini A, Roden MJEjoci. The role of mitochondria in statin-induced
 397 myopathy. 2015; 45(7): 745-54.

398 35. Zuo L-J, Piao Y-S, Li L-X, et al. Phenotype of postural instability/gait difficulty in Parkinson disease:

relevance to cognitive impairment and mechanism relating pathological proteins and
 neurotransmitters. 2017; 7(1): 44872.

401 36. Wen P, Li M, Xiao H, et al. Low-frequency stimulation of the pedunculopontine nucleus affects

402 gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats.

403 **2015; 600**: 62-8.

37. Basaia S, Agosta F, Francia A, et al. Cerebro-cerebellar motor networks in clinical subtypes of
Parkinson's disease. 2022; 8(1): 113.

406 38. Müller ML, Frey KA, Petrou M, et al. β-amyloid and postural instability and gait difficulty in

- 407 Parkinson's disease at risk for dementia. 2013; **28**(3): 296-301.
- 408 **39.** Li HH, Lin CL, Huang CN. Neuroprotective effects of statins against amyloid β-induced
- 409 neurotoxicity. *Neural Regen Res* 2018; **13**(2): 198-206.
- 410 40. Welter M-L, Demain A, Ewenczyk C, et al. PPNa-DBS for gait and balance disorders in Parkinson's
- 411 disease: a double-blind, randomised study. 2015; **262**: 1515-25.
- 412 41. El-Dessouki AM, Galal MA, Awad AS, Zaki HFJMn. Neuroprotective effects of simvastatin and
- 413 cilostazol in L-methionine-induced vascular dementia in rats. 2017; 54: 5074-84.

414



#### Figure 1 Instrument Selection for Lipid-lowering Drug Classes

The black line represents the DNA strand. The raised black box indicates the tar get gene, and the box with dashed line encompasses the region of ±100kb base pairs around the target gene. Each inverted triangle represents a genetic varian t. Disappearing of inverted triangles indicates the exclusion of variants. HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; MAF, minor allele frequency; NPC1L1, N iemann-Pick C1-like 1; PCSK9, proprotein convertase subtilisin/kexin type.

# Figure 2 Estimated Effects of Genetic Variation in Lipid-lowing Drug Targets on Lipid Metabolism-Related Traits (Panel A-B) and Obesity-Related Traits (Panel C-E)

A. Genetic variation in lipid-lowing drug targets on hyperlipidemia

Drug class	Proxy gene	Number of SNV	's	: OR (95% CI)	Р
HMGCR inhibitors	HMGCR	21		0.41 (0.34, 0.49)	1.61E-22
NPC1L1 inhibitors	NPC1L1	12	-	0.24 (0.18, 0.33)	1.17E-20
PCSK9 inhibitors	PCSK9	37	-	0.28 (0.25, 0.32)	4.85E-80
_		0	0 0.2 0.4 0.6 0.8	1 1.2	

**B.** Genetic variation in lipid-lowing drug targets on CAD

Drug class	Proxy gene	Number of SNVs	:	OR (95% CI)	Р
HMGCR inhibitors	HMGCR	19		0.70 (0.55, 0.89)	0.0031
NPC1L1 inhibitors	NPC1L1	10	_ <b>-</b>	0.48 (0.33, 0.70)	0.00014
PCSK9 inhibitors	PCSK9	29		0.51 (0.44, 0.60)	4.69E-16
		0.2	0.4 0.6 0.8 1	1.2	

C. Genetic variation in lipid-lowing drug targets on BMI

Drug class	Proxy gene	Number of SNVs	:		Beta (95% CI)	Р
HMGCR inhibitors	HMGCR	2			0.39 (0.32, 0.46)	1.72E-29
NPC1L1 inhibitors	NPC1L1	3	_		0.00 (-0.08, 0.07)	0.918
PCSK9 inhibitors	PCSK9	8	-		0.02 (-0.02, 0.06)	0.249
		.0.2		0.2 0.4	 	

**D.** Genetic variation in lipid-lowing drug targets on WC

Drug class	Proxy gene	Number of SNVs	:		Beta (95% CI)	Р
HMGCR inhibitors	HMGCR	20			0.25 (0.16, 0.33)	7.92E-09
NPC1L1 inhibitors	NPC1L1	11			-0.08 (-0.18, 0.02)	0.118
PCSK9 inhibitors	PCSK9	31	-		0.03 (0.00, 0.06)	0.021
		-0.4	-0.2 0	0.2	<b>一</b> 0.4	

E. Genetic variation in lipid-lowing drug targets on HC

Drug class	Proxy gene	Number of SNVs	:		Beta (95% CI)	Р
HMGCR inhibitors	HMGCR	20			0.29 (0.21, 0.38)	2.15E-12
NPC1L1 inhibitors	NPC1L1	11			-0.07 (-0.19, 0.05)	0.246
PCSK9 inhibitors	PCSK9	31	÷		0.00 (-0.03, 0.03)	0.932
		-0.4	-0.2 0	0.2 0.	4	

Proxy gene is the gene that encodes the drug target protein. The estimated bet a coefficients on BMI, WC, and HC are expected to be in agreement with the e vidence from clinical trials, that is, taking in HMGB1 inhibitor (ie, lovastatin) cont ributes to weight gain, and taking NPC1L1 inhibitor (ie, ezetimibe) and PCSK9 in hibitor (ie, alirocumab) has no effect on weight. BMI, body mass index; CAD, co

ronary artery disease; HC, hip circumference; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; IVs, instrumental variables; NPC1L1, Niemann-Pick C1-like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisin/kexin type; SNVs, single-nucleot ide variations; WC, waist circumference.

## Figure 3 Estimated Effects of Genetic Variation in Lipid-lowing Drug Targets on Parkinson's disease

A. Genetic variation in lipid-lowing drug targets on all types of PKD

Drug class	Proxy gene	Number of SNVs	:	OR (95% CI)	Р	<i>P</i> for heterogeneity	P for intercept
HMGCR inhibitors	HMGCR	20		0.54 (0.34, 0.86)	0.009	0.16	0.70
NPC1L1 inhibitors	NPC1L1	11		0.55 (0.25, 1.20)	0.135	0.86	0.36
PCSK9 inhibitors	PCSK9	27		— 1.01 (0.74, 1.38)	0.946	0.75	0.35
		00	0.5	15			

**B.** Genetic variation in lipid-lowing drug targets on TD vs PIGD

Drug class	Proxy gene	Number of SNVs	:			OR (95% CI)	Р	<i>P</i> for heterogeneity	P for intercept
HMGCR inhibitors	HMGCR	19				8.43(2.12, 33.52)	0.0025	0.70	0.16
NPC1L1 inhibitors	NPC1L1	11				13.09 (1.03, 166.64)	0.0475	0.42	0.44
PCSK9 inhibitors	PCSK9	21				0.28 (0.08, 0.94)	0.0398	0.46	0.64
		0.01	0.1	10	100				

Proxy gene is the gene that encodes the drug target proteins. P < 0.01 indicate s statistical significance, and 0.01 indicates suggestive significance. Pfor heterogeneity <0.05 indicates possible heterogeneity, whereas p for intercept <0.05 indicates substantial bias from pleiotropy. HMGCR, 3-hydroxy-3-methylglutar yl-CoA reductase; IVs, instrumental variables; MR, mendelian randomization; NPC1 L1, Niemann-Pick C1-like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisi n/kexin type; PIGD, postural instability/gait difficulty; PKD, Parkinson's disease; SN Vs, single-nucleotide variations; TD, tremor-dominant.

Drug class	Represen tative dr ug	Drug targ et ( <i>Encoding</i> gene)	Function of target protei n	Gene r egion
3-hydroxy-3-meth ylglutaryl-CoA reductase (HMGC R) inhibitors	Lovastati n	HMGCR ( <i>HMGCR</i> )	NADPH bind ing	Chr5:74 632154 - 746579 29
Niemann-Pick C1- like 1 (NPC1L1) inhibitors	Ezetimib e	NPC1L1 ( <i>NPC1L1</i> )	Rab GTPase binding	Chr7:44 552134 - 445809 14
Proprotein conve rtase subtilisin/ke xin type 9 (PCSK9) i nhibitors	Alirocum ab	PCSK9 ( <i>P</i> <i>CSK9</i> )	Very-low-den sity lipoprot ein particle rece ptor binding	Chr1:55 505221 - 5555305 25

# Table 1 Detailed Information of Lipid-lowering Drug Classes, Targets, and Encoding Genes.